Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Amble vs Oak

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.4

Amble

Best for mainstream telehealth GLP-1 access
★★★3.7

Starting at $179/mo

CompoundedSemaglutideTirzepatide
Visit Amble
7.6

Oak

Best for shoppers who want both compounded semaglutide and tirzepatide on one platform with a transparent flat monthly price
★★★3.8

Starting at $80/mo

CompoundedSemaglutideTirzepatideLegitScript Verified
Visit Oak

Side-by-Side Comparison

FeatureAmbleOak
Overall Score7.4/107.6/10
Starting Price$179/mo$80/mo
Editorial Rating3.7 ★ /53.8 ★ /5
Features3 features4 features
States Available500
Compounded✓ Yes✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Amble

Pros

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Cons

  • Limited public information on program details

Oak

Pros

  • Both compounded semaglutide ($130/mo) and tirzepatide ($199/mo) on a single platform
  • $50 off first month with code OAKNEW50
  • LegitScript-certified pharmacy network
  • No video call required for initial approval; flat per-month pricing across all dose strengths

Cons

  • Pharmacy partners are not publicly named on the marketing site (material gap for YMYL disclosure)
  • Operates in 45 states per Terms of Use, but the public state list is gated behind the signup intake
  • No brand-name Wegovy / Zepbound / Mounjaro / Ozempic available — compounded only
  • Fees are non-refundable per Terms of Use; binding arbitration under Delaware law

Our Verdict

Winner: OakScore: 7.6/10

Oak edges out Amble with a higher overall score of 7.6/10 and is particularly strong for shoppers who want both compounded semaglutide and tirzepatide on one platform with a transparent flat monthly price. Amble remains a solid alternative, especially if you're looking for mainstream telehealth GLP-1 access.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.